CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Madrigal Pharmaceuticals, Inc. (MDGL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Madrigal Pharmaceuticals, Inc. (MDGL)

Pharmaceutical Preparations · market cap $11.8B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Madrigal Pharmaceuticals (MDGL) is a ~$10.1B market-cap company with 528 employees. Its lead asset is resmetirom, which our database lists as Phase 3 for NASH, with additional Phase 3 and Phase 2 entries in heterozygous familial hypercholesterolemia (HeFH) under MGL-3196. Reported revenue of $180M in 2024 and $958M in 2025 conflicts with the 'Phase 3' stage label, so our pipeline field may lag the company's actual status. Two high-importance Phase 3 resmetirom catalysts are on our calendar (est. 2026-12-15 and est. 2027-03-15), plus earnings on 2026-11-03.
The catalyst path
  • 2026-12-15 (est.)Phase 3 · Resmetiromimp 9/10
  • 2027-03-15 (est.)Phase 3 · Resmetiromimp 9/10
Pipeline
AssetPhaseIndication
ResmetiromPhase 3NASH
MGL-3196Phase 3Heterozygous Familial Hypercholesterolemia
MGL-3196 (resmetirom)Phase 2Heterozygous Familial Hypercholesterolemia
Price & technical context
3-month
-18.5%
6-month
-18.1%
12-month
-17.0%
52-wk range
$396.32–$602.83
vs 50-day MA
-9.7%
vs 200-day MA
-13.8%
Realized vol
42.4%
Max drawdown
-34.3%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MDGL (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.